Effectiveness Oral Theophylline, Piracetam, and Iron Treatments in Children With Simple Breath-Holding Spells

Breath-holding spells (BHS) are common nonepileptic paroxysmal events in children. This is a retrospective study to compare the effectiveness of oral theophylline, piracetam, and iron treatments in children with simple BHS. A total of 146 children (75 girls and 71 boys) with simple BHS were included to this retrospective study. Children were divided into 4 groups: nontreated (no anemia and no treatment), oral theophylline (10 mg/kg/d as a single daily dose), piracetam (40 mg/kg/d in 2 divided doses), and elementary iron (3 mg/kg/d as a single daily dose) treatments. Iron therapy had been given only in children with iron deficiency anemia. Neurologic, cardiologic, and biochemical evaluations were performed for all children. The majority of the patients had cyanotic spells (83.6%). The frequency of attacks/month was markedly decreased with iron (58.8%) and theophylline (82.9%) treatments, but not with piracetam therapy (8.8%) and nontreated group (4.7%). Satisfaction of the parents/caregivers was found to be high in the theophylline group ( P < .001). Our results showed that theophylline was the most effective therapy to decrease the frequency of simple BHS in children.

Download Full-text

Effects of iron therapy on pituitary gonadal axis and sperm parameters in adults with iron deficiency anemia (IDA)

Endocrine Abstracts ◽

10.1530/endoabs.32.p643 ◽

2013 ◽

Author(s):

Ashraf Soliman ◽

Mohamed Yassin ◽

Osman Abdelrahmanm ◽

Vincenzo Desanctis ◽

Ahmed Elawwa

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Sperm Parameters ◽

Iron Therapy ◽

Deficiency Anemia

Download Full-text

IRON ABSORPTION AND RESPONSE TO ORAL IRON THERAPY IN IRON DEFICIENCY ANEMIA ASSOCIATED TO ASYMPTOMATIC GIARDIASIS.

Pediatric Research ◽

10.1203/00006450-199306000-00039 ◽

1993 ◽

Vol 33 (6) ◽

pp. 661-661

Author(s):

Helena U Suzuki ◽

Mauro B Morais ◽

Jose N Corral ◽

Ulisses Fagundes-Neto ◽

Nelson L Machado

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Iron Absorption ◽

Oral Iron ◽

Iron Therapy ◽

Deficiency Anemia ◽

Oral Iron Therapy

Download Full-text

Comparative Study of the Effects of Lactoferrin versus Oral Iron Therapy in Obese Children and Adolescents with Iron Deficiency Anemia

Journal of Advances in Medicine and Medical Research ◽

10.9734/jammr/2021/v33i2131138 ◽

2021 ◽

pp. 104-114

Author(s):

Manal Mahmoud Atia ◽

Rasha Mohamed Gama ◽

Mohamed Attia Saad ◽

Mohammed Amr Hamam

Keyword(s):

Iron Deficiency ◽

Children And Adolescents ◽

Iron Deficiency Anemia ◽

Interleukin 6 ◽

Oral Iron ◽

Iron Therapy ◽

Deficiency Anemia ◽

Obese Children ◽

Oral Iron Therapy ◽

Serum Hepcidin

Greater prevalence of iron deficiency (ID) has been observed in overweight and obese children and adolescents. Hepcidin acts as a key regulator of iron metabolism. Hepcidin synthesis increases in response inflammatory cytokines especially Interleukin-6 (IL-6). Considering that obesity represents a low grade chronic inflammatory state, a high concentration of hepcidin has been found in obese children. Elevated hepcidin level in obese children is associated with diminished response to oral iron therapy. Lactoferrin is an iron-binding multifunctional glycoprotein and has strong capacity to modulate the inflammatory response by its capacity to reduce pro-inflammatory cytokine expression in vivo, including IL-6 and hepcidin. Aim of the Work: To compare the efficacy of lactoferrin versus oral iron therapy in treatment of obese children and adolescents with iron deficiency anemia and the effect of therapy on serum hepcidin and interleukin 6 levels. Methodology: This prospective randomized clinical trial was conducted on 40 obese children and adolescents aged between 6 –18 years suffering from iron deficiency anemia (IDA). They were equally randomized into one of 2 groups. Group A received regular oral lactoferrin in a dose of 100 mg/day. Group B received regular oral iron supplementation (Ferric hydroxide polymaltose) in a dose of 6 mg elemental iron/kg /day.Baseline investigations included complete blood count (CBC), iron profile (Serum ferritin, serum iron, total iron binding capacity (TIBC), transferrin saturation), serum Interleukin 6, and serum hepcidin. Reevaluation of CBC was done monthly while iron status parameters, serum IL-6 and serum hepcidin were reevaluated after 3 months of receiving regular therapy. Results: Significant elevations in hemoglobin, MCV, MCH, Serum ferritin, serum iron and transferrin saturation with lactoferrin therapy compared to oral iron therapy. Significantly Lower TIBC after 3 months of lactoferrin therapy while the decrease in TIBC was insignificant in the iron therapy group.Lower serum hepcidin and IL6 after 3 months of lactoferrin therapy with no significant change in serum hepcidin and IL6 after iron therapy. Conclusion: This study clearly demonstrated the superiority of lactoferrin over iron use as oral in the treatment of iron deficiency anemia in obese children not only for the better response of hematological and iron status parameters and less gastrointestinal side effects but also for its effect on decreasing inflammatory biomarkers as hepcidin and IL6.

Download Full-text

Effect of Iron Therapy on the Whole Blood Platelet Aggregation in Infants with Iron Deficiency Anemia*

Thrombosis Research ◽

10.1016/s0049-3848(99)00150-4 ◽

2000 ◽

Vol 97 (5) ◽

pp. 281-285 ◽

Cited By ~ 11

Author(s):

Ahmet Emin Kürekçi ◽

A.Avni Atay ◽

S.Ümit Sarı́cı́ ◽

Cengiz Zeybek ◽

Vedat Köseoğlu ◽

...

Keyword(s):

Platelet Aggregation ◽

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Whole Blood ◽

Blood Platelet ◽

Iron Therapy ◽

Deficiency Anemia ◽

Blood Platelet Aggregation

Download Full-text

Iron Refractory Iron Deficiency Anemia: Presentation With Hyperferritinemia and Response to Oral Iron Therapy

PEDIATRICS ◽

10.1542/peds.2012-1303 ◽

2013 ◽

Vol 131 (2) ◽

pp. e620-e625 ◽

Cited By ~ 12

Author(s):

D.-A. Khuong-Quang ◽

J. Schwartzentruber ◽

M. Westerman ◽

P. Lepage ◽

K. E. Finberg ◽

...

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Oral Iron ◽

Iron Therapy ◽

Deficiency Anemia ◽

Oral Iron Therapy

Download Full-text

Hematologic Features of Iron Deficiency Anemia in Llamas

Veterinary Pathology ◽

10.1177/030098589202900505 ◽

1992 ◽

Vol 29 (5) ◽

pp. 400-404 ◽

Cited By ~ 20

Author(s):

D. E. Morin ◽

F. B. Garry ◽

M. G. Weiser ◽

M. J. Fettman ◽

L. W. Johnson

Keyword(s):

Iron Deficiency ◽

Cell Volume ◽

Iron Deficiency Anemia ◽

Hemoglobin Concentration ◽

Iron Therapy ◽

Deficiency Anemia ◽

Mean Corpuscular Hemoglobin ◽

Volume Distribution ◽

Mean Cell Volume ◽

Parenteral Iron

Iron deficiency anemia was identified and characterized in three 14 to 29-month-old male llamas (llama Nos. 1–3) from separate herds in Colorado. The identification of iron deficiency anemia was based on hypoferremia (serum iron = 20–60 μg/dl), erythrocytic features, and hematologic response to iron therapy. The anemia was moderate and nonregenerative and characterized by erythrocyte hypochromia, microcytosis (mean cell volume = 15–18 fl), and decreased mean corpuscular hemoglobin concentration (36.0–41.0 g/dl). Morphologic features unique to llamas with iron deficiency anemia included irregular distribution of hypochromia within erythrocytes and increased folded cells and dacryocytes. The cause of iron deficiency was not determined. The llamas were treated with various doses and schedules of parenteral iron dextran. Two of the llamas were monitored for up to 14 months after the start of iron therapy and experienced increases in hematocrit and mean cell volume values. In one llama, progressive replacement of microcytic cells with normal cells was visualized on sequential erythrocyte volume distribution histograms following iron therapy.

Download Full-text

IRON DEFICIENCY ANEMIA: EFFECTS OF IRON THERAPY ON INFANTS DEVELOPMENT TEST PERFORMANCE

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/00005176-199704000-00182 ◽

1997 ◽

Vol 24 (4) ◽

pp. 492

Author(s):

Henedina Antunes ◽

Sónia Gonçalves ◽

Mário Dinis-Ribeiro ◽

Altamiro Costa-Pereira ◽

M. Igreja-Beirão

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Test Performance ◽

Iron Therapy ◽

Deficiency Anemia

Download Full-text

Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open‐label, 6‐month extension study

American Journal of Hematology ◽

10.1002/ajh.24240 ◽

2016 ◽

Vol 91 (2) ◽

Cited By ~ 4

Author(s):

Saroj Vadhan‐Raj ◽

David C. Ford ◽

Naomi V. Dahl ◽

Kristine Bernard ◽

Zhu Li ◽

...

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Phase Iii ◽

Iron Therapy ◽

Deficiency Anemia ◽

Open Label ◽

Safety And Efficacy ◽

Episodic Treatment ◽

Oral Iron Therapy ◽

History Of

Download Full-text

Hematologic Effects of Levothyroxine in Iron-Deficient Subclinical Hypothyroid Patients: A Randomized, Double-Blind, Controlled Study

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2008-1440 ◽

2009 ◽

Vol 94 (1) ◽

pp. 151-156 ◽

Cited By ~ 26

Author(s):

Hakan Cinemre ◽

Cemil Bilir ◽

Feyzi Gokosmanoglu ◽

Talat Bahcebasi

Keyword(s):

Iron Deficiency ◽

Iron Deficiency Anemia ◽

Subclinical Hypothyroidism ◽

Serum Iron ◽

Oral Iron ◽

Iron Therapy ◽

Deficiency Anemia ◽

Controlled Study ◽

Iron Group ◽

Iron Deficient

Abstract Context: In patients with coexisting iron-deficiency anemia and subclinical hypothyroidism, anemia does not adequately respond to oral iron therapy. Objective: We studied whether iron-deficiency anemia might indicate treatment of subclinical hypothyroidism. Design: Patients were assigned to a control or experimental group: 240 mg/d oral iron alone (iron group) or 240 mg/d oral iron plus 75 μg/d levothyroxine (iron/levothyroxine group). Levels of hemoglobin, hematocrit, red blood cell count, serum iron levels, ferritin, total iron-binding capacity, TSH, and free T4 were measured before and after treatment. Setting: The study was conducted at a university hospital outpatient clinic. Patients: Fifty-one patients with coexisting iron-deficiency anemia and subclinical hypothyroidism participated in the study. Intervention: Patients were treated as described above in either the iron group or the iron/levothyroxine group. Main Outcome Measure: A clinically satisfactory increase in hemoglobin was regarded as successful. Results: Mean hemoglobin levels increased by 0.4 g/dl in the iron group [95% confidence interval (CI) 0.2–0.7, P = 0.001], whereas it increased by a mean of 1.9 g/dl in the iron/levothyroxine group (95% CI 1.5–2.3, P < 0.0001). The increase in serum iron was greater in the iron/levothyroxine group by a mean of 47.6 μg/dl (95% CI 34.5–60.6, P < 0.0001). Increases in hemoglobin, red blood cells, hematocrit, and serum ferritin levels after treatment were statistically significantly greater in the iron/levothyroxine group (P < 0.0001). Starting hemoglobin and increase in hemoglobin were negatively correlated in the iron/levothyroxine group (r = −0.531, P = 0.006). Conclusions: Subclinical hypothyroidism should be treated in iron-deficiency anemia patients when both conditions coexist. This would provide a desired therapeutic response to oral iron replacement and prevent ineffective iron therapy.

Download Full-text